| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BSG |
| Uniprot No | P35613 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 138-323aa |
| 氨基酸序列 | EPGTVFTTVEDLGSKILLTCSLNDSATEVTGHRWLKGGVVLKEDALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHGPPRVKAVKSSEHINEGETAMLVCKSESVPPVTDWAWYKITDSEDKALMNGSESRFFVSSSQGRSELHIENLNMEADPGQYRCNGTSSKGSDQAIITLRVRSHLA |
| 预测分子量 | 49.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BSG(Basigin/CD147)重组蛋白的3篇示例参考文献及其摘要概括(注：以下为模拟内容，实际文献请通过学术数据库检索)：
---
1. **文献名称**: *"Expression and functional characterization of recombinant human Basigin (CD147) in cancer cell invasion"*
**作者**: Zhang L, et al. (2018)
**摘要**: 该研究成功在大肠杆菌中表达了可溶性BSG重组蛋白，并验证其促进肿瘤细胞分泌基质金属蛋白酶(MMP-2/9)的能力。实验表明，重组BSG通过调控细胞间相互作用增强癌细胞侵袭性，提示其作为癌症治疗靶点的潜力。
2. **文献名称**: *"Structural insights into the interaction between Basigin and cyclophilin A using recombinant protein models"*
**作者**: Watanabe T, et al. (2020)
**摘要**: 通过X射线晶体学解析了重组BSG胞外结构域与亲环素A(CyPA)的复合物结构，揭示了二者结合的关键氨基酸位点。该研究为开发靶向BSG-CyPA相互作用的抗炎或抗病毒药物提供了结构基础。
3. **文献名称**: *"Recombinant Basigin as a novel biomarker for early detection of diabetic retinopathy"*
**作者**: Kim S, et al. (2021)
**摘要**: 利用哺乳动物细胞表达系统制备高纯度糖基化BSG重组蛋白，发现其在糖尿病患者血清中水平显著升高。临床数据分析表明，BSG可作为糖尿病视网膜病变的早期诊断标志物。
---
如需真实文献，建议在 **PubMed**(https://pubmed.ncbi.nlm.nih.gov/)或 **Google Scholar** 中搜索关键词：
`"Basigin recombinant protein"`、`"CD147 expression and purification"`、`"BSG structural analysis"`。
**Background of BSG Recombinant Protein**
BSG (Basigin), also known as CD147 or EMMPRIN (Extracellular Matrix Metalloproteinase Inducer), is a highly conserved transmembrane glycoprotein belonging to the immunoglobulin superfamily. It plays pivotal roles in diverse physiological and pathological processes, including cell adhesion, migration, immune regulation, and tumor progression. BSG is widely expressed in various tissues and interacts with multiple partners, such as integrins, cyclophilins, and monocarboxylate transporters (MCTs), to modulate cellular metabolism, inflammation, and tissue remodeling.
A hallmark feature of BSG is its ability to stimulate the production of matrix metalloproteinases (MMPs) in neighboring stromal cells, facilitating extracellular matrix degradation and promoting cancer invasion and metastasis. Additionally, BSG serves as a receptor for pathogens like *Plasmodium falciparum* (malaria parasite) and has been implicated in SARS-CoV-2 entry, highlighting its biomedical relevance.
Recombinant BSG protein is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functionally active forms for research and therapeutic applications. It typically retains key domains, such as the extracellular immunoglobulin-like regions critical for ligand binding. Researchers utilize BSG recombinant proteins to study its structural-functional relationships, develop targeted therapies (e.g., anti-cancer antibodies or malaria vaccines), and explore its role in diseases like rheumatoid arthritis and COVID-19.
The development of BSG-targeted strategies, including monoclonal antibodies and small-molecule inhibitors, underscores its potential as a therapeutic target. However, challenges remain in understanding its pleiotropic functions and tissue-specific interactions. Ongoing studies aim to unravel BSG's complex biology, paving the way for innovative treatments in oncology, infectious diseases, and inflammatory disorders.
×
